New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
12:31 EDTGS, BRK.A, SONC, RFMD, ZIOP, CLMTOn The Fly: Midday Wrap
Stocks on Wall Street were higher right out of the gate and have not moved far from their opening levels near midday. Investors received a fair amount of domestic economic data, including better than expected reports on home prices and durable goods orders. The flip side, however, was some worse than expected consumer confidence and new home sales data. Despite the mixed data, the market seems intent on closing the quarter with its gains intact as the end of the month approaches... ECONOMIC EVENTS: In the U.S., overall orders for durable goods rose 5.7% in February, versus expectations for an increase of 3.9%. However, excluding transportation, orders slipped 0.5%, versus expectations for a 0.6% rise. The S&P/Case-Shiller 20-city home price index climbed 8.1% in the 12 months ending in January, after rising 6.8% a month earlier. New home sales dropped 4.6% to 411K in February, versus expectations for a decline to 414K. Consumer confidence fell 8.3 points to 59.7 in March, which was worse than the expected pull back to 69.0. The Richmond Fed manufacturing survey reading of 3 for March missed expectations for it to hold at 6... COMPANY NEWS: Goldman Sachs (GS) announced that it amended its warrant agreement with Berkshire Hathaway (BRK.A) to settle in terms of net shares in place of a cash settlement, quoting Berkshire's Chairman and CEO Warren Buffett as having said, "We intend to hold a significant investment in Goldman Sachs." Shares of Goldman, which rose early in the session, were down fractionally near noon... MAJOR MOVERS: Among the notable gainers were Sonic (SONC), which rose 8% following its earnings report, and RF Micro Devices (RFMD), which rallied nearly 6% after Oppenheimer upgraded the stock to an Outperform rating. Among the noteworthy losers was Ziopharm (ZIOP), which was downgraded by at least four analyst firms and plunged over 61% after terminating development of a cancer drug after a clinical study missed its goal. Also lower were shares of Calumet Specialty Products (CLMT), down 4% after an offering of 5.25M of its shares priced at $37.50... INDICES: Near midday, the Dow was up 74.84, or 0.52%, to 14,522.59; the Nasdaq was up 5.90, or 0.18%, to 3,241.20; and the S&P 500 was up 6.36, or 0.41%, to 1,558.05.
News For A;SONC;RFMD;ZIOP;CLMT From The Last 14 Days
Check below for free stories on A;SONC;RFMD;ZIOP;CLMT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
11:43 EDTRFMDOptions with increasing implied volatility
Options with increasing implied volatility: UUP TLM RFMD ALTR NI
09:03 EDTRFMDRF Micro Devices management to meet with Brean Capital
Subscribe for More Information
July 22, 2014
08:08 EDTRFMDPeregrine, RF Micro Devices settle all outstanding litigation
Peregrine Semiconductor (PSMI) and RF Micro Devices (RFMD) announced that they have settled all outstanding claims between the companies. The two parties have entered into patent cross licenses and have agreed to dismiss all related litigation. Specific financial terms of the agreement remain confidential.
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
July 21, 2014
13:23 EDTRFMDHigh option volume stocks: RFMD LCI MR PII DG CTRL
Subscribe for More Information
July 17, 2014
18:31 EDTRFMDOn The Fly: After Hours Movers
Subscribe for More Information
06:20 EDTAAgilent initiated with a Neutral at Citigroup
Target $64.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use